Literature DB >> 9403869

Tissue matrix protein expression in human osteoblasts, osteosarcoma tumors, and osteosarcoma cell lines.

J Bidwell1, R McCabe, B Rougraff, H Feister, E Fey, J Onyia, J Holden, J Hock.   

Abstract

Treatment for osteosarcoma is problematic because there are no prognostic markers. Diagnosis is primarily limited to cytologic grading. Oncogenesis alters cell structure therefore osteoblast tissue matrix proteins (extracellular matrix, cytoskeletal, intermediate filament, and nuclear matrix proteins), components of the cell substructure, are candidates for osteosarcoma markers. Structural proteins of the extracellular matrix, e.g. the collagens, are useful for diagnosis but not for tumors that produce little osteoid. To identify principal cellular tissue matrix proteins that distinguish normal from transformed human osteoblasts, their expression in normal osteoblasts, two osteosarcoma cell lines, and three primary osteosarcoma tumors were compared. The tumors were graded as (i) intermediate, (ii) high, and (iii) high grade recurrent. The 1-D SDS/PAGE profiles of the major components of the nuclear matrix and intermediate filament fractions from normal osteoblasts did not vary with biopsy site, age, or sex of patients. These profiles included known cytoskeletal proteins and OB250, a approximately 250 kD protein(s) observed in the intermediate filament fraction. A loss of protein bands, including OB250, was observed in the osteosarcoma cell lines and tumors. The intermediate and high grade tumors exhibited nearly identical protein profiles including potential tumor-specific proteins and collagen, consistent with the presence of intracellular collagen fibers in osteosarcoma. A microsequence was obtained for OT25, a novel low molecular weight protein observed in osteosarcoma cell lines. Fibrinogen gamma-chain, a protein that mediates cell adhesion was recovered from the high grade recurrent tumor.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9403869     DOI: 10.1023/a:1006883528518

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  41 in total

1.  Immunohistochemical and biochemical studies on the collagenous proteins of human osteosarcomas.

Authors:  Y Ueda; I Nakanishi
Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol       Date:  1989

Review 2.  Medical aspects of the actin cytoskeleton.

Authors:  P A Janmey; C Chaponnier
Journal:  Curr Opin Cell Biol       Date:  1995-02       Impact factor: 8.382

Review 3.  DNA topoisomerases and topoisomerase inhibitors.

Authors:  G Giaccone
Journal:  Pathol Biol (Paris)       Date:  1994-04

4.  Hepatoma-associated nuclear matrix nonhistone antigens.

Authors:  Z Kilianska; W M Krajewska; R L Xie; L Klyszejko-Stefanowicz; J F Chiu
Journal:  J Cell Biochem       Date:  1991-03       Impact factor: 4.429

5.  Expression of SPARC in normal and fibrotic livers.

Authors:  E Frizell; S L Liu; A Abraham; I Ozaki; M Eghbali; E H Sage; M A Zern
Journal:  Hepatology       Date:  1995-03       Impact factor: 17.425

6.  A common set of nuclear matrix proteins in prostate cancer cells.

Authors:  K J Pienta; J E Lehr
Journal:  Prostate       Date:  1993       Impact factor: 4.104

7.  Effects of extracellular matrix components and dihydrotestosterone on the structure and function of human prostate cancer cells.

Authors:  B C Murphy; K J Pienta; D S Coffey
Journal:  Prostate       Date:  1992       Impact factor: 4.104

8.  Nuclear matrix proteins in human colon cancer.

Authors:  S K Keesee; M D Meneghini; R P Szaro; Y J Wu
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-01       Impact factor: 11.205

9.  Higher level organization of individual gene transcription and RNA splicing.

Authors:  Y Xing; C V Johnson; P R Dobner; J B Lawrence
Journal:  Science       Date:  1993-02-26       Impact factor: 47.728

10.  Bone cancers.

Authors:  H D Dorfman; B Czerniak
Journal:  Cancer       Date:  1995-01-01       Impact factor: 6.860

View more
  2 in total

Review 1.  Potential of human γδ T cells for immunotherapy of osteosarcoma.

Authors:  Zhaoxu Li
Journal:  Mol Biol Rep       Date:  2012-10-14       Impact factor: 2.316

Review 2.  DAMPening inflammation by modulating TLR signalling.

Authors:  A M Piccinini; K S Midwood
Journal:  Mediators Inflamm       Date:  2010-07-13       Impact factor: 4.711

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.